摘要
目的探讨微小RNA-141(miR-141)在多囊卵巢综合征(PCOS)患者卵巢颗粒细胞中的表达,并评价其临床意义。方法选取70例PCOS患者,根据体质量指数(BMI)分为正常体质量组(BMI<25,n=42)和肥胖组(BMI≥25,n=28);选取同期71例对照患者,分为正常体质量组(BMI<25,n=60)和肥胖组(BMI≥25,n=11)。采用逆转录实时定量PCR(qRT-PCR)检测各组卵巢颗粒细胞中miR-141的表达,并分析其临床意义。结果 PCOS正常体质量组中miR-141的表达高于对照正常体质量组(P<0.001);与对照肥胖组相比,miR-141在PCOS肥胖组中高表达(P=0.009)。此外,PCOS患者妊娠并发症发生率有升高的趋势,但差异无统计学意义(P>0.0125)。结论 PCOS患者正常体质量组与肥胖组中miR-141的表达水平分别高于其相对应的对照患者,且PCOS患者发生妊娠并发症的风险有升高的趋势,提示miR-141可能在PCOS的发病机制中发挥重要作用。
Objective To investigate the expression of microRNA-141(miR-141) in ovarian granulosa cells of patients with polycystic ovary syndrome(PCOS) and its clinical significance. Methods A total of 70 PCOS patients were divided into normal-BMI group(BMI<25, n=42) and obesity group(BMI≥25, n=28) according to their(BMI), and 71 controls were divided into normal-BMI group(BMI<25, n=60) and obesity group(BMI≥25, n=11). The expression of miR-141 in ovarian granulosa cells of each group was detected with real-time quantitative reverse transcription PCR(qRT-PCR), and its clinical significance was analyzed. Results The expression of miR-141 was higher in the normal-BMI PCOS group than in the normal-BMI control group(P<0.001);and compared with obesity control group, higher expression of miR-141 was observed in obesity PCOS group(P=0.009). In addition, the incidence of pregnancy complications in PCOS patients tended to be higher, but there was no statistical significance(P>0.0125). Conclusion The expression of miR-141 is higher in the PCOS groups than in the control groups. and the risk of pregnancy complications tends to increase in PCOS patients, suggesting that miR-141 may play an important role in the pathogenesis of PCOS.
作者
贺婷婷
刘红
舒凯云
宋晓翠
石玉华
HE Tingting;LIU Hong;SHU Kaiyun;SONG Xiaocui;SHI Yuhua(Shandong Provincial Clinical Medicine Research Center for Reproductive Health, Jinan 250001, Shandong, China;Department of Reproductive Medicine, Second Hospital of Shandong University, Jinan 250033, Shandong, China)
出处
《山东大学学报（医学版）》
CAS
北大核心
2019年第5期116-120,共5页
Journal of Shandong University:Health Sciences
基金
国家重点研发计划(2018YFC1003200,2017YFC1001004)
泰山学者工程专项经费(ts201712103)
